logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Folate Analog Metabolic Inhibitor class drugs

    FiltersReset Filters
    4 results

    • folotyn

      (pralatrexate)
      Acrotech Biopharma Inc
      Usage: FOLOTYN is indicated for treating patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Its approval is based on overall response rates, with continued approval dependent on confirmation of clinical benefits in future trials.

    • otrexup

      (methotrexate)
      Antares Pharma, Inc.
      Usage: Otrexup is indicated for managing severe, active rheumatoid arthritis in adults and children with polyarticular juvenile idiopathic arthritis, as well as for the symptomatic control of severe psoriasis in adults unresponsive to other treatments. It is not for neoplastic diseases.

    • rasuvo

      (methotrexate)
      Medexus Pharma Inc.
      Usage: Rasuvo is indicated for managing severe, active rheumatoid arthritis in adults and polyarticular juvenile idiopathic arthritis in children, where first-line treatments are ineffective or intolerable. It also treats severe, recalcitrant psoriasis in adults with an established diagnosis. Not recommended for neoplastic diseases.

    • xatmep

      (Methotrexate)
      Azurity Pharmaceuticals, Inc.
      Usage: XATMEP is indicated for treating pediatric patients with acute lymphoblastic leukemia (ALL) as part of a chemotherapy regimen and managing active polyarticular juvenile idiopathic arthritis (pJIA) in those who respond inadequately or are intolerant to first-line therapies, including NSAIDs.